Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 363 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: LDL Clear all

Conditions: Acute Coronary Syndrome
Interventions: Inclisiran; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 88
States / cities: Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 19
States / cities: Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more

Conditions: Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 20
States / cities: Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more

Conditions: Metabolic Syndrome X, Insulin Resistance
Interventions: fenofibrate, niacin, rosiglitazone; Drug
Lead sponsor: Foundation Research, Florida; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Acute Coronary Artery Syndrome
Interventions: intensive LDL-lowering therapy, standard statin monotherapy; Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 31 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more

Conditions: Cholesterol Metabolism, Ketone Metabolism
Interventions: Standard American diet, Very low carbohydrate diet; Other
Lead sponsor: Touro University, California; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Vallejo, California

Conditions: Macular Degeneration
Interventions: Celecoxib (Celebrex); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Heart Health Screening and Prevention
Interventions: Fingerstick cholesterol test, Atherosclerosis Cardiovascular Disease Risk assessment, Blood pressure measurement; Procedure · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cardiovascular Disease, Oxidative Stress
Interventions: Chokeberry Extract, Placebo capsule, Chokeberry extract capsule, acute; Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Dyslipidemia
Interventions: LCP-AtorFen; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiovascular Outcomes
Interventions: Niaspan, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Evolocumab, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib, Ezetimibe 10mg, Obicetrapib placebo, Ezetimibe placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 16
States / cities: Los Angeles, California • Northridge, California • Ocala, Florida + 13 more

Conditions: Metabolic Syndrome
Interventions: Simvastatin, Vytorin, Placebo, Ezetimibe; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Coronary Artery Disease
Interventions: Inclisiran sodium 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 27
States / cities: Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more

Conditions: Orbital Atrophy
Interventions: fat, PRP, botulinum toxin, botulinum toxin, PRP; Procedure · Drug · Device
Lead sponsor: Fox, Donald Munro, M.D., P.C.; Individual
Eligibility: 21 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: mipomersen, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Risk Factor, Type2 Diabetes Mellitus, Insulin Sensitivity, Metabolic Syndrome
Interventions: Naturally-sweetened orange juice, Sugar-sweetened beverage; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Cardiovascular
Interventions: Chitin-Glucan, Low Dose Chitin-Glucan, Low Dose Chitin-Glucan + Olive Extract, Placebo; Dietary Supplement
Lead sponsor: Stratum Nutrition; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Addison, Illinois • Louisville, Kentucky

Conditions: Severe Familial Hypercholesterolemia
Interventions: Evolocumab; Biological
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Pathological Processes in the Posterior Fossa, Dura Defects
Interventions: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care; Biological · Procedure
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 3 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 12
States / cities: Duarte, California • Sacramento, California • San Diego, California + 9 more

Conditions: HIV Infections, Dyslipidemias
Interventions: Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution; Drug
Lead sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 50 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

Investigating the Production of Lipoproteins and Acetyl-CoA During a Ketogenic Diet

Laser and Medical Treatment of Diabetic Macular Edema

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Beauty from Within Community Screening Project

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Benefit of Elevation of HDL-C in Women

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.

Study of Venous Endothelial Cells in Rheumatoid Arthritis

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)

Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects

Orange Juice And Sugar Intervention Study

Effects of Chitin-Glucan on Oxidized Low-Density Lipoprotein (LDL)

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Fibrin Sealant for the Sealing of Dura Sutures

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)